Restricted accessReview articleFirst published online 2026-1
Assessing Long-Term Feasibility and Efficacy of Treatments for Retinal Vein Occlusion Macular Edema: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
This network meta-analysis (NMA) of randomized controlled trials (RCTs) evaluates the long-term efficacy and feasibility of treatments for macular edema (ME) secondary to retinal vein occlusion (RVO). Comparisons between different alternatives remain unclear.
Methods:
We used a Bayesian framework to perform an NMA of treatments for ME secondary to RVO. We searched for relevant RCTs with at least 12 months of follow-up in PubMed, Scopus, Web of Science, and Cochrane databases. Efficacy outcomes included changes in best-corrected visual acuity and central macular thickness, while feasibility outcomes focused on the mean number of injections and dropout rates.
Results:
We included 3,431 patients from 21 RCTs. We compared 8 treatment modalities: aflibercept, ranibizumab 0.3, ranibizumab 0.5 mg, bevacizumab, dexamethasone, dexamethasone plus anti- Vascular Endothelial Growth Factor (VEGF), laser, and anti-VEGF plus laser. Dexamethasone combined with anti-VEGF treatment was found to be the most effective and feasible. Aflibercept was the top option when used alone, followed by bevacizumab and ranibizumab. Laser alone, dexamethasone alone, and laser combined with anti-VEGF treatment showed the lowest long-term effectiveness and feasibility.
Conclusion:
Dexamethasone plus anti-VEGF is a potential long-term option for effectiveness. Despite the need for repeated injections, aflibercept stands out as a leading choice.
MoriokaM, TakamuraY, NagaiK, et al.Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics. Sci Rep, 2020; 10(1):22122; doi: 10.1038/s41598-020-79377-w
2.
GaoS, ZhangY, LiX, et al.Comparative efficacy of pharmacotherapy for macular edema secondary to retinal vein occlusion: A network meta-analysis. Front Pharmacol, 2021; 12:752048; doi: 10.3389/fphar.2021.752048
GrzybowskiA, MarkeviciuteA, ZemaitieneR. Treatment of macular edema in vascular retinal diseases: A 2021 Update. J Clin Med, 2021; 10(22):5300; doi: 10.3390/jcm10225300
5.
WangH, WangC, ZhangS, et al.Impact of anti-VEGF therapy on distinctive retina layers in patients with macular edema secondary to branch retinal vein occlusion. BMC Ophthalmol, 2023; 23(1):235; doi: 10.1186/s12886-023-02981-7
6.
JumperJM, DugelPU, ChenS, et al.Anti-VEGF treatment of macular edema associated with retinal vein occlusion: Patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophthalmol, 2018; 12:621–629; doi: 10.2147/OPTH.S163859
7.
KelkarA, WebersC, ShettyR, et al.Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol, 2020; 68(10):2143–2147; doi: 10.4103/ijo.IJO_1866_19
8.
RegnierSA, MalcolmWA. Efficacy comparison of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: A systematic review and network meta-analysis. Value in Health, 2015; 18(7):A416; doi: 10.1371/journal.pone.0102309
9.
FordJA, ShyangdanD, UthmanOA, et al.Drug treatment of macular oedema secondary to central retinal vein occlusion: A network meta-analysis. BMJ Open, 2014; 4(7):e005292; doi: 10.1136/bmjopen-2014-005292
10.
SangroongruangsriS, RatanapakornT, WuO, et al.Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: A systematic review and network meta-analysis. Expert Rev Clin Pharmacol, 2018; 11(9):903–916; doi: 10.1080/17512433.2018.1507735
11.
RussoV, BaroneA, ConteE, et al.Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina, 2009; 29(4):511–515; doi: 10.1097/IAE.0b013e318195ca65
12.
BrownDM, CampochiaroPA, BhisitkulRB, et al.Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology, 2011; 118(8):1594–1602; doi: 10.1016/j.ophtha.2011.02.022
13.
CampochiaroPA, BrownDM, AwhCC, et al.Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study. Ophthalmology, 2011; 118(10):2041–2049; doi: 10.1016/j.ophtha.2011.02.038
14.
DonatiS, BarosiP, BianchiM, et al.Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol, 2012; 22(4):607–614; doi: 10.5301/ejo.5000085
15.
HeierJS, ClarkWL, BoyerDS, et al.Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: Two-year results from the COPERNICUS study. Ophthalmology, 2014; 121(7):1414–1420.e1; doi: 10.1016/j.ophtha.2014.01.027
16.
OguraY, RoiderJ, KorobelnikJ-F, et al.; GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol, 2014; 158(5):1032–1038; doi: 10.1016/j.ajo.2014.07.027
17.
ParodiMB, IaconoP, BandelloF. Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment. Graefes Arch Clin Exp Ophthalmol, 2015; 253(10):1647–1651; doi: 10.1007/s00417-014-2845-6
18.
TanMH, McAllisterIL, GilliesME, et al.Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol, 2014; 157(1):237–247.e1; doi: 10.1016/j.ajo.2013.08.013
19.
ClarkWL, BoyerDS, HeierJS, et al.Intravitreal Aflibercept for macular edema following branch retinal vein occlusion: 52-Week results of the VIBRANT study. Ophthalmology, 2016; 123(2):330–336; doi: 10.1016/j.ophtha.2015.09.035
20.
LotfyA, SolaimanKAM, AbdelrahmanA, et al.Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina, 2018; 38(9):1795–1800; doi: 10.1097/IAE.0000000000001782
21.
PichiF, ElbarkyAM, ElhamakyTR. Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. Int Ophthalmol, 2019; 39(1):145–153; doi: 10.1007/s10792-017-0798-6
22.
TadayoniR, WaldsteinSM, BosciaF, et al.; BRIGHTER Study Group. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology, 2017; 124(12):1778–1787; doi: 10.1016/j.ophtha.2017.06.027
23.
BandelloF, AugustinA, TufailA, et al.A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol, 2018; 28(6):697–705; doi: 10.1177/1120672117750058
24.
HykinP, PrevostAT, VasconcelosJC, et al.; LEAVO Study Group. Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: A randomized clinical trial. JAMA Ophthalmol, 2019; 137(11):1256–1264; doi: 10.1001/jamaophthalmol.2019.3305
25.
Casselholm de SallesM, AmrénU, KvantaA, et al.Injection frequency of aflibercept versus ranibizumab in a treat-and-extend regimen for central retinal vein occlusion: A randomized clinical trial. Retina, 2019; 39(7):1370–1376; doi: 10.1097/IAE.0000000000002171
26.
WeiW, WeisbergerA, ZhuL, et al.; BLOSSOM Study Group. Efficacy and safety of ranibizumab in Asian patients with branch retinal vein occlusion: Results from the randomized BLOSSOM study. Ophthalmol Retina, 2020; 4(1):57–66; doi: 10.1016/j.oret.2019.08.001
27.
SongS, YuX, ZhangP, et al.Combination of ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: One-year results from a randomized controlled double-blind trial. BMC Ophthalmol, 2020; 20(1):241; doi: 10.1186/s12886-020-01498-7
28.
LimonU, Sezgin AkçayBI. Add-on effect of simultaneous intravitreal dexamethasone to intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion. J Ocul Pharmacol Ther, 2022; 38(2):183–188; doi: 10.1089/jop.2021.0100
29.
MurataT, KondoM, InoueM, et al.The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients. Sci Rep, 2021; 11(1):551; doi: 10.1038/s41598-020-79051-1
30.
FrederiksenKH, VestergaardJP, PedersenFN, et al.Navigated laser and aflibercept versus aflibercept monotherapy in treatment-naïve branch retinal vein occlusion: A 12-month randomized trial. Acta Ophthalmol, 2022; 100(7):e1503–e1509; doi: 10.1111/aos.15182
31.
OjimaA, KatoY, TomitaR, et al.MACULAR sensitivity change after complementary laser therapy after ranibizumab intravitreal injection in branch retinal vein occlusion. Retina, 2023; 43(6):999–1004; doi: 10.1097/IAE.0000000000003749
32.
SterneJAC, SavovićJ, PageMJ, et al.RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 2019; 366:l4898.
33.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021; 372:n71; doi: 10.1136/bmj.n71
34.
MoherD, LiberatiA, TetzlaffJ, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 2009; 6(7):e1000097; doi: 10.1371/journal.pmed.1000097
35.
van de SchootR, DepaoliS, KingR, et al.Bayesian statistics and modelling. Nat Rev Methods Primers, 2021; 1(1); doi: 10.1038/s43586-020-00001-2
36.
HarrerM, CuijpersP, FurukawaT, et al.Doing Meta-Analysis with R: A Hands-On Guide. CRC Press; 2021; doi: 10.1201/9781003107347
37.
TodorichB, ThanosA, YonekawaY, et al.Simultaneous dexamethasone intravitreal implant and anti-VEGF therapy for neovascular age-related macular degeneration resistant to anti-VEGF monotherapy. J Vitreoretin Dis, 2017; 1(1):65–74; doi: 10.1177/2474126416683299
38.
VakalisN, EchiadisG, PervenaA, et al.Intravitreal combination of dexamethasone sodium phosphate and bevacizumab in the treatment of exudative AMD. Sci Rep, 2015; 5:8627; doi: 10.1038/srep08627
39.
CaiX, ZhaoJ, DangY. Combination therapy with anti-VEGF and intravitreal dexamethasone implant for macular edema secondary to retinal vein occlusion. Curr Eye Res, 2024; 49(8):872–878; doi: 10.1080/02713683.2024.2343055
40.
SingerMA, JansenME, TylerL, et al.Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: An investigational case series. Clin Ophthalmol, 2017; 11:31–38; doi: 10.2147/OPTH.S119373
41.
ChiS-C, KangY-N, HuangY-M. Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: A systematic review and meta-analysis. Sci Rep, 2023; 13(1):7428; doi: 10.1038/s41598-023-34673-z
42.
Veiga ReisF, DalgalarrondoP, da Silva Tavares NetoJE, et al.Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): A phase I clinical study. Int J Retina Vitreous, 2023; 9(1):13; doi: 10.1186/s40942-023-00449-w
43.
KhuranaRN, ChangLK, BansalAS, et al.Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study. Int J Retina Vitreous, 2019; 5:10; doi: 10.1186/s40942-019-0159-x
44.
SpoonerK, Fraser-BellS, HongT, et al.Effects of switching to aflibercept in treatment resistant macular edema secondary to retinal vein occlusion. Asia Pac J Ophthalmol (Phila), 2020; 9(1):48–53; doi: 10.1097/01.APO.0000617924.11529.88
45.
OzkayaA, TuluB, GaripR. Aflibercept in macular edema secondary to retinal vein occlusion: A real life study. Saudi J Ophthalmol, 2017; 31(4):211–215; doi: 10.1016/j.sjopt.2017.09.009
46.
CampochiaroPA, HafizG, MirTA, et al.Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: The RELATE trial. Ophthalmology, 2015; 122(7):1426–1437; doi: 10.1016/j.ophtha.2015.04.006
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
